Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: A randomized control study

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 1, 2010, Pages 30-38

  Spadaccio, Cristiano ^a   Pollari, Francesco ^a   Casacalenda, Adele ^a   Alfano, Gennaro ^b   Genovese, Jorge ^a   Covino, Elvio ^a   Chello, Massimo ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Atorvastatin; Cardiopulmonary bypass surgery; Endothelial progenitor cells

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

AGED; ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; ELECTIVE SURGERY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HEART SURGERY; HUMAN; MALE; PHENOTYPE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEM CELL; TREATMENT DURATION;

AGED; ANTICHOLESTEREMIC AGENTS; CARDIOPULMONARY BYPASS; CHOLESTEROL; CROSS-OVER STUDIES; CYTOKINES; DOUBLE-BLIND METHOD; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRROLES; TIME FACTORS;

EID: 75749154054     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181c37d4d     Document Type: Article

References (52)

1. Kawamoto A, Losordo DW. Endothelial progenitor cells for cardiovascular regeneration. Trends Cardiovasc Med. 2008;18:33-37.
2. Roncalli JG, Tongers J, Renault MA, et al. Endothelial progenitor cells in regenerative medicine and cancer: a decade of research. Trends Biotechnol. 2008;26:276-283.
3. Doyle B, Metharom P, Caplice NM. Endothelial progenitor cells. Endothelium. 2006;13:403-410.
4. Goon PK, Watson T, Stonelake PS, et al. Endothelial progenitor cells: from pathophysiology to clinical practice. Int J Clin Pract. 2008;62:4-6.
5. Tian F, Liang PH, Li LY. Inhibition of endothelial progenitor cell differentiation by VEGI. Blood. 2009;113:5352-5360.
6. Yamahara K, Itoh H. Potential use of endothelial progenitor cells for regeneration of the vasculature. Ther Adv Cardiovasc Dis. 2009;3:17-27.
7. Geft D, Schwartzenberg S, George J. Circulating endothelial progenitor cells in cardiovascular disorders. Expert Rev Cardiovasc Ther. 2008;6: 1115-1121.
8. Gurtner GC, Chang E. "Priming" endothelial progenitor cells: a new strategy to improve cell based therapeutics. Arterioscler Thromb Vasc Biol. 2008;28:1034-1035.
9. Jujo K, II M, Losordo DW. Endothelial progenitor cells in neovascularization of infarcted myocardium. J Mol Cell Cardiol. 2008;45: 530-544.
10. Roberts N, Xiao Q, Weir G, et al. Endothelial progenitor cells are mobilized after cardiac surgery. Ann Thorac Surg. 2007;83:598-605.
11. Sekiguchi H, II M, Losordo DW. The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J Cell Physiol. 2009;219: 235-242.
12. Mund JA, Ingram DA, Yoder MC, et al. Endothelial progenitor cells and cardiovascular cell-based therapies. Cytotherapy. 2009;11:103-113.
13. Leone AM, Rutella S, Giannico MB, et al. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. Int J Cardiol. 2008; 130:457-462.
14. Kang HJ, Lee HY, Na SH, et al. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colonystimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation. 2006; 114(Suppl 1):I145-I151.
15. Gomez-Cerezo JF, Pagan-Munoz B, Lopez-Rodriguez M, et al. The role of endothelial progenitor cells and statins in endothelial function: a review. Cardiovasc Hematol Agents Med Chem. 2007;5:265-272.
16. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res. 2009;81:519-527.
17. Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cardiothorac Surg. 2005;28:805-810.
18. Chello M, Patti G, Candura D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med. 2006;34:660-667.
19. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006; 114:1455-1461.
20. Leone AM, Rutella S, Bonanno G, et al. Mobilization of bone marrowderived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005;26:1196-1204.
21. Leone AM, Rutella S, Bonanno G, et al. Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol. 2006; 111:202-208.
22. Rupp S, Badorff C, Koyanagi M, et al. Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells. Basic Res Cardiol. 2004;99: 61-68.
23. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391-397.
24. Suzuki G, Iyer V, Cimato T, et al. Pravastatin improves function in hibernating myocardium by mobilizing CD133+ and cKit+ bone marrow progenitor cells and promoting myocytes to reenter the growth phase of the cardiac cell cycle. Circ Res. 2009;104:255-264; 10 pages following 264.
25. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-2890.
26. Müller P, Kazakov A, Jagoda P, et al. ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload. Cardiovasc Res. 2009;83:106-114.
27. Bauersachs J, Widder J. Endothelial dysfunction in heart failure. Pharmacol Rep. 2008;60:119-126.
28. Mieno S, Ramlawi B, Boodhwani M, et al. Role of stromal-derived factor- 1alpha in the induction of circulating CD34+CXCR4+ progenitor cells after cardiac surgery. Circulation. 2006;114(Suppl 1):I186-I192.
29. Rubba P. Effects of atorvastatin on the different phases of atherogenesis. Drugs. 2007;67(Suppl 1):17-27.
30. Scheubel RJ, Zorn H, Silber RE, et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol. 2003;42:2073-2080.
31. Rustemeyer P, Wittkowski W, Jurk K, et al. Optimized flow cytometric analysis of endothelial progenitor cells in peripheral blood. J Immunoassay Immunochem. 2006;27:77-88.
32. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105:3017-3024.
33. Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004;110:1933-1939.
34. Spyridopoulos I, Haendeler J, Urbich C, et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation. 2004;110:3136-3142.
35. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858-864.
36. Wojakowski W, Tendera M, Michalowska A, et al. Mobilization of CD34/ CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation. 2004;110: 3213-3220.
37. Wojakowski W, Tendera M, Zebzda A, et al. Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J. 2006;27:283-289.
38. Zohlnhofer D, Ott I, Mehilli J, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA. 2006;295:1003-1010.
39. Kollet O, Petit I, Kahn J, et al. Human CD34(+)CXCR4(-) sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood. 2002;100:2778-2786.
40. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845-848.
41. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3:687-694.
42. Abbott JD, Huang Y, Liu D, et al. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation. 2004;110:3300-3305.
43. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964-3972. (Pubitemid 29335849)
44. Powell TM, Paul JD, Hill JM, et al. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2005;25:296-301.
45. Shao H, Tan Y, Eton D, et al. Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells. 2008;26:1376-1384.
46. Sun W, Lee TS, Zhu M, et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation. 2006;114:2655-2662.
47. Li X, Han Y, Pang W, et al. AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008;28:1789-1795.
48. Henrich D, Seebach C, Wilhelm K, et al. High dosage of simvastatin reduces TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. J Surg Res. 2007; 142:13-19.
49. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003;92: 1049-1055.
50. Minami Y, Satoh M, Maesawa C, et al. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur J Clin Invest. 2009;39: 359-367.
51. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1-E7.
52. Walter DH, Haendeler J, Reinhold J, et al. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ Res. 2005;97:1142-1151.